Citations

Showing 10 of 108162 citations.

Cirrhotic Cardiomyopathy Predicts Posttransplant Cardiovascular Disease: Revelations of the New Diagnostic Criteria
Izzy, Manhal , Angirekula, Mounika, Mara, Kristin C. , Lin, Grace , Watt, Kymberly D. , Soldatova, Anna, Sun, Xin , Mara, Kristin, Watt, K D , Mara, Kristin C , Soldatova, Anna M. , Sun, Xin

Mayo Clinic

Liver Transplantation | February 5, 2021 | Volume: 27 | Issue: 6 | Pages: 876-886

10.1002/lt.26000 | PMID 33533556 Get It

The diagnostic criteria for cirrhotic cardiomyopathy (CCM) were recently revised to reflect the contemporary advancements in echocardiographic technology. This study evaluates the prevalence of CCM, according to the new criteria, and its impact on posttransplant cardiovascular disease (CVD). This is a single‐center retrospective matched cohort study of liver transplantation (LT) recipients who underwent LT between January 1, 2008 and November 30, 2017. A total of 3 cohorts with decompensated cirrhosis (nonalcoholic steatohepatitis, alcohol‐related liver disease, or other etiologies) were matched based on age, sex, and year of transplant after excluding patients listed without evidence of hepatic decompensation. CCM was defined, according to 2020 criteria, as having diastolic dysfunction, left ventricular ejection fraction ≤50%, and/or a global longitudinal strain (GLS) absolute value <18%. The study echocardiographers were blinded to the clinical data. Posttransplant CVD included new coronary artery disease, congestive heart failure, atrial and ventricular arrhythmia, and stroke. The study included 141 patients of whom 59 were women. The mean age at LT was 57.8 (±7.6) years. A total of 49 patients (34.8%) had CCM. Patients with CCM were at an increased risk for post‐LT CVD (hazard ratio, 2.57; 95% confidence interval, 1.2‐5.5; P = 0.016). Changes in CCM individual parameters pretransplant, such as GLS, early diastolic transmitral flow to early diastolic mitral annular velocity, and left atrial volume index were associated with an increased risk for posttransplant CVD. CCM, defined by the new diagnostic criteria, affects approximately one‐third of decompensated LT candidates. CCM predicts an increased risk for new CVD following LT. Studies into addressing and follow‐up to mitigate these risks are needed.
Bivalirudin in Pediatric Extracorporeal Membrane Oxygenation: Clarity or Confusion?
Seelhammer, Troy G. , Bohman, J. Kyle , Nabzdyk, Christoph S. , Nabzdyk, Christoph , Bohman, John K

Mayo Clinic

ASAIO Journal | February 5, 2021 | Volume: 67 | Issue: 6 | Pages: 697-699

10.1097/mat.0000000000001364 | PMID 33528167 Get It

Development of CAR-T Cell Constructs with Broad Anti-Tumor Tropism
Mishra, A. , Kemler, Iris, Dingli, David

Mayo Clinic

Blood | February 5, 2021 | Volume: 136 | Issue: Supplement 1 | Pages: 24-24

10.1182/blood-2020-136704 Get It

Chimeric antigen receptor T (CAR-T) cell therapy is a transformative approach to cancer eradication. CAR-T is expensive in part due to the restricted use of each CAR construct for a specific set of tumors such as B cell lymphoma targeted with CD19 and multiple myeloma targeted with BCMA. A CAR construct with broad anti-tumor activity can be advantageous due to wide applicability and scalability of production. We show that CD126, the IL-6 receptor alpha, is an antigen that is expressed by many hematologic and solid malignancies including multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, pancreatic and prostate adenocarcinoma, non-small cell lung cancer and malignant melanoma amongst others. High CD126 expression is a negative prognostic marker in many malignancies. The two CD126 targeting CAR-T cell constructs contain the CD28 anchoring domain followed by 4-1BB and CD3 zeta signaling domain. Lentiviral vectors were generated with triple plasmid (CAR, psPAX2 and pMD2.G) transfection of 293T cells and the vector concentrated by ultracentrifugation and used to transduce human T cells. T cells were isolated from leuko-reduction cones using negative selection with magnetic beads. The transduction efficiency was around 60%. The T cells were activated with anti-CD3/CD28 beads and expanded for two weeks before using for downstream experiments. CD126 CAR-T cells are able to kill many tumor cells in an antigen specific manner and with an efficiency that is directly proportional to the cell surface expression of CD126 expression (rho = 0.6, p = 0.0019). The presence of soluble CD126 in the culture media did not interfere with CAR-T cell killing. The CAR-T constructs bind murine CD126. However, injection of CD126 targeting CAR-T cells in NSG mice did not lead to any evidence of hepatotoxicity and weight loss despite possible expression of this antigen on hepatocytes. In vivo studies in NSG mice with multiple myeloma (RPMI-8226) and prostate adenocarcinoma (DU-145) xenograft models (n=10 tumors per group) showed that the intravenously injected CD126 targeted CAR-T cells (107) infiltrated the tumors, expanded, produced human interferon gamma and killed the tumor cells (p&lt;0.001). Bioluminescence imaging showed control of tumor growth in the actively treated tumors compared to the controls (p&lt;0.05). At post mortem, mice injected with CD126 targeted CAR-T cells had smaller residual tumors compared to controls injected with non-engineered human T cells from the same donor. Binding of sIL-6R by CAR-T cells could mitigate cytokine release syndrome. In support of this, murine SAA-3 levels (the equivalent of human CRP) were lower in mice injected with CD126 CAR-T compared to controls (p&lt;0.05), suggesting that binding of sIL-6R by CAR-T cells could mitigate cytokine release syndrome. CD126 provides a novel therapeutic for CAR-T cells in a broad variety of tumors with low risk of toxicity. Disclosures Dingli: Apellis: Consultancy; Millenium: Consultancy; Janssen: Consultancy; Bristol Myers Squibb: Research Funding; Sanofi-Genzyme: Consultancy; Alexion: Consultancy; Rigel: Consultancy; Karyopharm Therapeutics: Research Funding.
Priorities, actions and risks in the COVID-19 pandemic: a flash SoMe survey among surgical oncologists
Cortés‐Guiral, Delia , Sgarbură, Olivia , Alyami, Mohammad , Yoshida, Kazuhiro , Doki, Yuichiro� , Ishigami, Hironori , Hübner, Martin , Hübner, Martin , Grass, Fabian

Mayo Clinic

Pleura and Peritoneum | February 5, 2021 | Volume: 6 | Issue: 1 | Pages: 7-12

10.1515/pp-2020-0142 | PMID 34222646 Get It

Abstract Objectives Corona virus-induced disease 19 (COVID-19) pandemic has globally affected the surgical treatment of cancer patients and has challenged the ethical principles of surgical oncologists around the world. Not only treatment but also diagnosis and follow-up have been disrupted. Methods An online survey was sent through Twitter and by the surgical societies worldwide. The survey consisted of 29 closed-ended questions and was conducted over a period of 24 days beginning in March 26, 2020. Results Overall, 394 surgical oncologists from 41 different countries answered the questionnaire. The predominant guiding principle was “saving lives” 240 (62%), and the different aspects of lock-down found hence large support (mean 7.1–9.3 out of 10). Shut-down of elective surgery and modification of cancer care found a mean support of 7.0 ± 3.0 and 5.8 ± 3.1, respectively. Modification of cancer care longer than two weeks was considered unacceptable to 114 (29%) responders. Hundred and fifty six (40%) and 138 (36%) expect “return to normal” beyond six months for surgical practice and cancer care, respectively. Conclusions Surgical oncologists show strong and long-lasting support for lock-down measures aiming to save lives. The impact of the pandemic on surgical oncology is perceived controversially, but the majority was forced already now to accept what is inacceptable for many of their colleagues.
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)
Barajas, Ramon , Politi, Letterio S. , Anzalone, Nicoletta , Schöder, Heiko , Fox, Christopher P. , Quarles, C. Chad , Ellingson, Benjamin M. , Auer, Dorothee P. , Andronesi, Ovidiu C. , Ferreri, Andrés J.M. , Mrugała, Maciej M. , Neuwelt, Edward A. , Ambady, Prakash , Rubenstein, James L. , Illerhaus, Gerald , Nagane, Motoo , Batchelor, Tracy T. , Hu, Leland , Barajas, Ramon F , Ellingson, Benjamin M , Nagane, Motoo , Schöder, Heiko , Fox, Christopher P , Boxerman, Jerrold L. , Kaufmann, Timothy J. , Grommes, Christian

Mayo Clinic

Neuro-Oncology | February 5, 2021 | Volume: 23 | Issue: 7 | Pages: 1056-1071

10.1093/neuonc/noab020 | PMID 33560416 Get It

Abstract Advanced molecular and pathophysiologic characterization of primary central nervous system lymphoma (PCNSL) has revealed insights into promising targeted therapeutic approaches. Medical imaging plays a fundamental role in PCNSL diagnosis, staging, and response assessment. Institutional imaging variation and inconsistent clinical trial reporting diminishes the reliability and reproducibility of clinical response assessment. In this context, we aimed to: (1) critically review the use of advanced positron emission tomography (PET) and magnetic resonance imaging (MRI) in the setting of PCNSL; (2) provide results from an international survey of clinical sites describing the current practices for routine and advanced imaging, and (3) provide biologically based recommendations from the International PCNSL Collaborative Group (IPCG) on adaptation of standardized imaging practices. The IPCG provides PET and MRI consensus recommendations built upon previous recommendations for standardized brain tumor imaging protocols (BTIP) in primary and metastatic disease. A biologically integrated approach is provided to addresses the unique challenges associated with the imaging assessment of PCNSL. Detailed imaging parameters facilitate the adoption of these recommendations by researchers and clinicians. To enhance clinical feasibility, we have developed both “ideal” and “minimum standard” protocols at 3T and 1.5T MR systems that will facilitate widespread adoption.
Brain Science Under the Swastika: Ethical Violations, Resistance and Victimization of Neuroscientists in Nazi Europe
Wijdicks, Eelco F. M.

Mayo Clinic

Journal of the History of the Neurosciences | February 5, 2021 | Volume: 30 | Issue: 2 | Pages: 220-222

10.1080/0964704x.2021.1880843 Get It

Telemedicine in International Cleft Care: A Systematic Review
Bedi, Gurbani , Vyas, Krishna S. , Chung, Michael T. , Morrison, Shane D. , Asaad, Malke , Mardini, Samir

Mayo Clinic

The Cleft Palate Craniofacial Journal | February 5, 2021 | Volume: 58 | Issue: 12 | Pages: 1547-1555

10.1177/1055665621989140 | PMID 33535816 Get It

Background: Cleft lip and cleft palate (CLP) are among the world’s most common congenital malformation and has a higher prevalence in developing nations due to environmental and genetic factors. Global efforts have been developed in order to prevent and treat the malformation. Telemedicine has been implemented in various humanitarian global missions with success and is currently the primary means of care due to COVID-19. Objective: To assess the benefits and barriers of telehealth in the care of patients with CLP through a global approach. Methods: Systematic review of the PubMed and Cochrane Review databases with relevant terms related to telemedicine in cleft lip and palate surgery. Results: Eight articles fit the inclusion criteria and suggested benefits with the use of telemedicine in regard to education, preoperative, and postoperative care as well as increased access to underserved populations. Barriers included connectivity and accessibility concerns. Conclusion: Telehealth is a beneficial way to evaluate patients with CLP in developing countries with proper care and follow-up to reduce complications and to improve health outcomes.
De Novo Colorectal and Pancreatic Cancer in Liver‐Transplant Recipients: Identifying the Higher‐Risk Populations
Nasser‐Ghodsi, Navine , Mara, Kristin C. , Watt, Kymberly D. , Mara, Kristin, Mara, Kristin C

Mayo Clinic

Hepatology | February 5, 2021 | Volume: 74 | Issue: 2 | Pages: 1003-1013

10.1002/hep.31731 | PMID 33544906 Get It

Background and Aims Gastrointestinal (GI) malignancies are common after liver transplantation. The aim of this study was to identify the risk and timing of the more common GI malignancies, colorectal and pancreatic cancer, to aid in optimizing potential posttransplant screening practices. Approach and Results Data from the United Network for Organ Sharing database of all adult liver‐transplant recipients from 1997 to 2017 were analyzed and a comparison made with cancer incidence from general population data using Surveillance, Epidemiology, and End Results data. Of 866 de novo GI malignancies, 405 colorectal and 216 pancreas were identified. The highest cumulative incidence for colorectal cancer occurred in recipients with primary sclerosing cholangitis (PSC), recipients over the age of 50 with non‐alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC)/cholangiocarcinoma (CCA), and females >50 years with alcohol‐associated liver disease and HCC/CCA, with risk increasing above the general population within 5 years of transplant. Patients with PSC and HCC/CCA or NASH and HCC/CCA have the highest cumulative incidence of pancreatic cancer also rising within 5 years following transplant, with those patients >50 years old conferring the highest risk. Conclusions These data identify a high‐risk cohort that warrants consideration for intensified individualized screening practices for colorectal cancer after liver transplantation. In addition to recipients with PSC, further study of recipients with NASH and HCC/CCA and females with alcohol‐associated liver disease and HCC/CCA may be better tailored to colorectal cancer screening ideals. Higher‐risk patient populations for pancreatic cancer (PSC and NASH with HCC/CCA) would benefit from further study to determine potential screening practices. GI malignancies occur at higher rates in liver‐transplant patients compared with the general population. In the era of individualized medicine, this study identifies the highest‐risk transplant recipients (PSC and NASH cirrhosis with coexisting HCC/CCA) who may benefit from altered screening practices for these malignancies.
Migraine treatment and COVID‐19 vaccines: No cause for concern
Gelfand, Amy A. , Poland, Gregory, Gelfand, Amy A , Poland, Gregory A.

Mayo Clinic

Headache: The Journal of Head and Face Pain | February 5, 2021 | Volume: 61 | Issue: 3 | Pages: 409-411

10.1111/head.14086 | PMID 33543775 Get It

Discovery and Opportunities With Integrative Analytics Using Multiple‐Omics Data
Athreya, Arjun P. , Lazaridis, Konstantinos N. , Lazaridis, Konstantinos N

Mayo Clinic

Hepatology | February 5, 2021 | Volume: 74 | Issue: 2 | Pages: 1081-1087

10.1002/hep.31733 | PMID 33539039 Get It